Gyongyi Horvath

List of Publications by Year
in descending order

97 papers	1,850 citations	279798 23 h-index	361022 35 g-index
134 all docs	134 docs citations	134 times ranked	1820 citing authors

#	Article	IF	Citations
1	Wisket rat model of schizophrenia: Impaired motivation and, altered brain structure, but no anhedonia. Physiology and Behavior, 2022, 244, 113651.	2.1	3
2	Fentanyl but Not Morphine or Buprenorphine Improves the Severity of Necrotizing Acute Pancreatitis in Rats. International Journal of Molecular Sciences, 2022, 23, 1192.	4.1	7
3	Effects of D2 dopamine receptor activation in the ventral pallidum on sensory gating and food-motivated learning in control and schizophrenia model (Wisket) rats. Behavioural Brain Research, 2021, 400, 113047.	2.2	0
4	Caffeine â€“ treat or trigger? Disparate behavioral and long-term dopaminergic changes in control and schizophrenia-like Wisket rats. Physiology and Behavior, 2021, 236, 113410.	2.1	5
5	Interaction of clozapine with metformin in a schizophrenia rat model. Scientific Reports, 2021, 11, 16862.	3.3	4
6	A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 10016.	4.1	5
7	Sleep-Wake Rhythm and Oscillatory Pattern Analysis in a Multiple Hit Schizophrenia Rat Model (Wisket). Frontiers in Behavioral Neuroscience, 2021, 15, 799271.	2.0	2
8	Distinct changes in chronic pain sensitivity and oxytocin receptor expression in a new rat model (Wisket) of schizophrenia. Neuroscience Letters, 2020, 714, 134561.	2.1	13
9	Characterization of dopamine D2 receptor binding, expression and signaling in different brain regions of control and schizophrenia-model Wisket rats. Brain Research, 2020, 1748, 147074.	2.2	10
10	Synthesis, biochemical, pharmacological characterization and in silico profile modelling of highly potent opioid orvinol and thevinol derivatives. European Journal of Medicinal Chemistry, 2020, 191, 112145.	5.5	7
11	Impaired GAD1 expression in schizophreniaâ€related WISKET rat model with sexâ€dependent aggressive behavior and motivational deficit. Genes, Brain and Behavior, 2019, 18, e12507.	2.2	9
12	Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules, 2019, 24, 3709.	3.8	16
13	Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors. European Journal of Medicinal Chemistry, 2019, 178, 571-588.	5.5	20
14	Cognitive training improves the disturbed behavioral architecture of schizophrenia-like rats, â€œWisketâ€• Physiology and Behavior, 2019, 201, 70-82.	2.1	8
15	Automating, Analyzing and Improving Pupillometry with Machine Learning Algorithms. Acta Cybernetica, 2019, 24, 197-209.	0.6	1
16	Trunk alignment in different standing positions in healthy subjects and stroke patients -a comparative study with a simple method for the everyday practice.: Trunk alignment in healthy and stroke subjects. Topics in Stroke Rehabilitation, 2018, 25, 561-568.	1.9	0
17	Impaired pupillary control in â€œschizophrenia-likeâ€•WISKET rats. Autonomic Neuroscience: Basic and Clinical, 2018, 213, 34-42.	2.8	10
18	Electroporation-enhanced transdermal diclofenac sodium delivery into the knee joint in a rat model of acute arthritis. Drug Design, Development and Therapy, 2018, Volume 12, 1917-1930.	4.3	10

#	Article	IF	Citations
19	Characterization of exploratory activity and learning ability of healthy and â€œschizophrenia-likeâ€•rats in a square corridor system (AMBITUS). Physiology and Behavior, 2017, 169, 155-164.	2.1	14
20	VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis. Documenta Ophthalmologica, 2017, 134, 185-193.	2.2	18
21	The Development and Aging of the Magnocellular and Parvocellular Visual Pathways as Indicated by VEP Recordings between 5 and 84 Years of Age. Vision (Switzerland), 2017, 1, 7.	1.2	10
22	Reduced mucosal side-effects of acetylsalicylic acid after conjugation with tris-hydroxymethyl-aminomethane. Synthesis and biological evaluation of a new anti-inflammatory compound. European Journal of Pharmacology, 2016, 781, 181-189.	3.5	6
23	Electrophysiological alterations in a complex rat model of schizophrenia. Behavioural Brain Research, 2016, 307, 65-72.	2.2	17
24	Postural control in degenerative diseases of the hip joint. Clinical Biomechanics, 2016, 35, 1-6.	1.2	9
25	Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia. Neuroscience Letters, 2016, 633, 87-93.	2.1	22
26	Mu-Opioid (MOP) receptor mediated G-protein signaling is impaired in specific brain regions in a rat model of schizophrenia. Neuroscience Letters, 2016, 619, 29-33.	2.1	24
27	Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science. PLoS ONE, 2015, 10, e0143751.	2.5	20
28	Telemetry monitoring for non-invasive assessment of changes in core temperature after spinal drug administration in freely moving rats. Journal of Pharmacological and Toxicological Methods, 2015, 72, 19-25.	0.7	6
29	Sex-specific alterations in behavioral and cognitive functions in a â€œthree hitâ€•animal model of schizophrenia. Behavioural Brain Research, 2015, 284, 85-93.	2.2	27
30	In vivo potency of different ligands on voltage-gated sodium channels. European Journal of Pharmacology, 2015, 762, 158-164.	3.5	4
31	The inimitable kynurenic acid: The roles of different ionotropic receptors in the action of kynurenic acid at a spinal level. Brain Research Bulletin, 2015, 112, 52-60.	3.0	26
32	Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty. Archives of Orthopaedic and Trauma Surgery, 2014, 134, 449-457.	2.4	9
33	The effects of juvenile capsaicin desensitization in rats: Behavioral impairments. Physiology and Behavior, 2014, 125, 38-44.	2.1	11
34	Characterization of geneâ€“environment interactions by behavioral profiling of selectively bred rats: The effect of NMDA receptor inhibition and social isolation. Behavioural Brain Research, 2013, 240, 134-145.	2.2	31
35	The Effects of Peptide and Lipid Endocannabinoids on Arthritic Pain at the Spinal Level. Anesthesia and Analgesia, 2012, 114, 1346-1352.	2.2	19
36	Characterization of antinociceptive potency of endomorphin-2 derivatives with unnatural amino acids in rats. Acta Physiologica Hungarica, 2012, 99, 353-363.	0.9	7

#	Article	IF	Citations
37	When does mechanical plantar stimulation promote sensory re-weighing: standing on a firm or compliant surface?. European Journal of Applied Physiology, 2012, 112, 2979-2987.	2.5	27
38	Neurochemistry of Endogenous Antinociception. Advances in Neurobiology, 2011, , 417-535.	1.8	0
39	Inhibition of itch-related responses at spinal level in rats. Acta Physiologica Hungarica, 2011, 98, 480-490.	0.9	8
40	The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level. Pharmacology Biochemistry and Behavior, 2011, 99, 731-737.	2.9	10
41	Long-lasting, distinct changes in central opioid receptor and urinary bladder functions in models of schizophrenia in rats. European Journal of Pharmacology, 2011, 661, 35-41.	3.5	11
42	Biomechanical comparison of three cemented stem removal techniques in revision hip surgery. Archives of Orthopaedic and Trauma Surgery, 2011, 131, 1007-1012.	2.4	6
43	Synovial fluid Î²-endorphin level in avascular necrosis, rheumatoid arthritis, and osteoarthritis of the femoral head and knee. A controlled pilot study. Clinical Rheumatology, 2011, 30, 537-540.	2.2	12
44	Antinociception by endogenous ligands at peripheral level. Ideggyogyaszati Szemle, 2011, 64, 193-207.	0.7	2
45	Peripheral antinociceptive effect of 2â€arachidonoylâ€glycerol and its interaction with endomorphinâ€1 in arthritic rat ankle joints. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 544-550.	1.9	14
46	The antinociceptive interaction of anandamide and adenosine at the spinal level. Pharmacology Biochemistry and Behavior, 2009, 91, 374-379.	2.9	4
47	Anti-inflammatory effects of phosphatidylcholine in neutrophil leukocyte-dependent acute arthritis in rats. European Journal of Pharmacology, 2009, 622, 58-64.	3.5	75
48	ANTINOCICEPTIVE INTERACTIONS BETWEEN ANANDAMIDE AND ENDOMORPHINâ€1 AT THE SPINAL LEVEL. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 400-405.	1.9	12
49	Selective disturbance of pain sensitivity after social isolation. Physiology and Behavior, 2009, 96, 18-22.	2.1	29
50	The Peripheral Antinociceptive Effects of Endomorphin-1 and Kynurenic Acid in the Rat Inflamed Joint Model. Anesthesia and Analgesia, 2009, 109, 1297-1304.	2.2	32
51	Pattern-reversal electroretinograms and visual evoked potentials in retinitis pigmentosa. Documenta Ophthalmologica, 2008, 117, 27-36.	2.2	12
52	The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain, 2008, 134, 277-284.	4.2	57
53	QUANTITATIVE CHARACTERIZATION OF A REPEATED ACUTE JOINT INFLAMMATION MODEL IN RATS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 520-526.	1.9	17
54	Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. Brain Research, 2007, 1155, 42-48.	2.2	11

#	Article	IF	Citations
55	Postural control in elderly subjects participating in balance training. European Journal of Applied Physiology, 2007, 100, 97-104.	2.5	93
56	Interaction of endogenous ligands mediating antinociception. Brain Research Reviews, 2006, 52, 69-92.	9.0	21
57	Evaluation of ketamine systemic absorption from topical preparations. Acta Biologica Hungarica, 2006, 57, 387-389.	0.7	8
58	Long-Term Changes in the Antinociceptive Potency of Morphine or Dexmedetomidine After a Single Treatment. Anesthesia and Analgesia, 2005, 101, 812-818.	2.2	13
59	In vitro and in vivo percutaneous absorption of topical dosage forms: case studies. International Journal of Pharmaceutics, 2005, 291, 11-19.	5.2	42
60	Relationship between breath-hold time and physical performance in patients with cystic fibrosis. European Journal of Applied Physiology, 2005, 95, 172-178.	2.5	10
61	Dose-independent antinociceptive interaction of endogenous ligands at the spinal level. Brain Research, 2004, 1029, 93-102.	2.2	10
62	Postural control in athletes participating in an ironman triathlon. European Journal of Applied Physiology, 2004, 92, 407-13.	2.5	98
63	Pharmacological and functional biochemical properties of d-Ala2-d-Nle5-enkephalin-Arg-Phe. Regulatory Peptides, 2004, 122, 139-146.	1.9	3
64	The Antinociceptive Potencies and Interactions of Endogenous Ligands During Continuous Intrathecal Administration: Adenosine, Agmatine, and Endomorphin-1. Anesthesia and Analgesia, 2004, 98, 420-426.	2.2	20
65	Evaluation of endomorphin-1 on the activity of Na+,K+-ATPase using in vitro and in vivo studies. European Journal of Pharmacology, 2003, 458, 291-297.	3.5	17
66	Antinociceptive activity ofSempervivum tectorum L. extract in rats. Phytotherapy Research, 2003, 17, 1032-1036.	5.8	13
67	Role of Na+,K+-ATPase in Morphine-Induced Antinociception. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 1122-1128.	2.5	28
68	The Significance of Intrathecal Catheter Location in Rats. Anesthesia and Analgesia, 2003, 96, 487-492.	2.2	8
69	High-dose Remifentanil Does Not Impair Cerebrovascular Carbon Dioxide Reactivity in Healthy Male Volunteers. Anesthesiology, 2003, 99, 834-840.	2.5	35
70	The Significance of Intrathecal Catheter Location in Rats. Anesthesia and Analgesia, 2003, 96, 487-492.	2.2	26
71	Upregulation of mu opioid receptors by voluntary morphine administration in drinking water. Acta Biologica Hungarica, 2003, 54, 157-166.	0.7	8
72	Chronic Morphine-Induced Changes in Î¼-Opioid Receptors and G Proteins of Different Subcellular Loci in Rat Brain. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 774-780.	2.5	52

#	Article	IF	Citations
73	The antinociceptive effect of intrathecal kynurenic acid and its interaction with endomorphin-1 in rats. European Journal of Pharmacology, 2002, 445, 93-96.	3.5	19
74	Uncoupling protein 2 (UCP2) lowers alcohol sensitivity and pain threshold. Biochemical Pharmacology, 2002, 64, 369-374.	4.4	31
75	Blood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal level. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366, 270-275.	3.0	13
76	Role of calcium channels in the spinal transmission of nociceptive information from the mesentery. Pain, 2001, 93, 35-41.	4.2	13
77	Antinociceptive effect of continuous intrathecal administration of endomorphin-1. Pain, 2001, 94, 31-38.	4.2	22
78	The Synergistic Antinociceptive Interactions of Endomorphin-1 with Dexmedetomidine and/or S(+)-Ketamine in Rats. Anesthesia and Analgesia, 2001, 93, 1018-1024.	2.2	55
79	Antinociceptive effect of continuous intrathecal infusion of endomorphin-1 in rats. European Journal of Anaesthesiology, 2001, 18, 139.	1.7	0
80	The Effects of Ketamine and Its Enantiomers on the Morphine- or Dexmedetomidine-induced Antinociception after Intrathecal Administration in Rats. Anesthesiology, 2000, 93, 231-241.	2.5	50
81	Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous Î¼-opioid receptor agonists. , 2000, 88, 437-463.		113
82	Effect of intrathecal agmatine on inflammation-induced thermal hyperalgesia in rats. European Journal of Pharmacology, 1999, 368, 197-204.	3.5	40
83	Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. Life Sciences, 1999, 65, 2635-2641.	4.3	51
84	Multiple nitric oxide sources in neurogenic plasma extravasation in rat hindpaw skin. Life Sciences, 1998, 63, 1119-1125.	4.3	6
85	Antinociceptive Effect of the S(+)-Enantiomer of Ketamine on Carrageenan Hyperalgesia after Intrathecal Administration in Rats. Anesthesia and Analgesia, 1998, 86, 561-565.	2.2	41
86	Antinociceptive Effect of the S(+)-Enantiomer of Ketamine on Carrageenan Hyperalgesia after Intrathecal Administration in Rats. Anesthesia and Analgesia, 1998, 86, 561-565.	2.2	30
87	ANTINOCICEPTIVE EFFECTS OF THE HYDROPHILIC Î±2-ADRENOCEPTOR AGONIST ST-91 IN DIFFERENT TEST CIRCUMSTANCES AFTER INTRATHECAL ADMINISTRATION TO WISTAR RATS. Pharmacological Research, 1997, 35, 561-568.	7.1	0
88	Drugs acting on calcium channels modulate the diuretic and micturition effects of dexmedetomidine in rats. Life Sciences, 1996, 59, 1247-1257.	4.3	10
89	An ultrasonographic method for the evaluation of dexmedetomidine on micturition in intact rats. Journal of Pharmacological and Toxicological Methods, 1994, 32, 215-218.	0.7	15
90	Mydriatic and antinociceptive effects of intrathecal dexmedetomidine in conscious rats. European Journal of Pharmacology, 1994, 253, 61-66.	3.5	15

#	Article	IF	Citations
91	Dexmedetomidine-induced decrease in cerebral blood flow is attenuated by verapamil in rats: a laser Doppler study. Canadian Journal of Anaesthesia, 1993, 40, 748-754.	1.6	10
92	An isobolographic analysis of the hypnotic effects of combinations of dexmedetomidine with fentanyl or diazepam in rats. Life Sciences, 1992, 50, PL215-PL220.	4.3	13
93	Potentiated hypnotic action with a combination of fentanyl, a calcium channel blocker and an Î±2â€agonist in rats. Acta Anaesthesiologica Scandinavica, 1992, 36, 170-174.	1.6	11
94	Calcium channels are involved in the hypnotic-anesthetic action of dexmedetomidine in rats. Anesthesia and Analgesia, 1992, 74, 884-8.	2.2	14
95	Drugs acting at calcium channels can influence the hypnotic-anesthetic effect of dexmedetomidine. Acta Biochimica Et Biophysica Hungarica, 1991, 26, 75-81.	0.1	1
96	Enhancement of fentanyl analgesia by clonidine plus verapamil in rats. Anesthesia and Analgesia, 1990, 70, 284-8.	2.2	11
97	Determination of activation energies and half-lives of thermoluminescence bands of chloroplasts applying the method of multicomponent curve resolution. FEBS Letters, 1980, 116, 293-297.	2.8	12